Published in J Pathol on June 27, 2011
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol (2012) 1.23
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis (2012) 1.11
Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell (2014) 1.04
Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene (2015) 0.83
Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis (2012) 0.82
Identification and comparison of aberrant key regulatory networks in breast, colon, liver, lung, and stomach cancers through methylome database analysis. PLoS One (2014) 0.82
Sapacitabine for cancer. Expert Opin Investig Drugs (2012) 0.81
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. Br J Cancer (2014) 0.80
The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget (2013) 0.80
The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma. PLoS One (2015) 0.76
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget (2017) 0.75
Transcriptional changes caused by bisphenol A in Oryzias javanicus, a fish species highly adaptable to environmental salinity. Mar Drugs (2014) 0.75
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget (2016) 0.75
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Small-cell lung cancer. Lancet (2011) 3.61
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst (2007) 3.11
The use of morphological characteristics and texture analysis in the identification of tissue composition in prostatic neoplasia. Hum Pathol (2004) 2.94
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax (2011) 2.88
BRCA1: mechanisms of inactivation and implications for management of patients. Lancet (2002) 2.85
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res (2007) 2.58
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res (2003) 2.51
The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst (2004) 2.49
Chinese herbal uropathy and nephropathy. Lancet (2006) 2.27
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 2.25
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol (2008) 1.99
Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS (2010) 1.92
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol (2003) 1.92
Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res (2009) 1.87
Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 1.87
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer (2010) 1.74
Guidelines on the radical management of patients with lung cancer. Thorax (2010) 1.73
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol (2005) 1.69
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer (2010) 1.66
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst (2014) 1.66
Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2009) 1.66
Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. Kidney Int (2010) 1.64
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer (2011) 1.53
HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem (2009) 1.52
Histone acetylation and chromatin pattern in cancer. A review. Anal Quant Cytol Histol (2007) 1.51
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45
Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol (2008) 1.43
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 1.42
Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all? Thorax (2011) 1.38
Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer (2004) 1.37
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol (2006) 1.31
Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg (2007) 1.31
INTS3 controls the hSSB1-mediated DNA damage response. J Cell Biol (2009) 1.31
Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res (2005) 1.30
BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res (2010) 1.29
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res (2009) 1.28
New advances in the second-line treatment of small cell lung cancer. Oncologist (2009) 1.25
The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol (2010) 1.22
Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg (2008) 1.21
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res (2007) 1.19
BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist (2007) 1.19
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat (2009) 1.16
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg (2004) 1.16
BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res (2005) 1.15
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol (2008) 1.14
Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology (2012) 1.13
Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer (2002) 1.13
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther (2008) 1.12
Substrate recognition and catalysis by the Holliday junction resolving enzyme Hje. Nucleic Acids Res (2004) 1.12
Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg (2009) 1.09
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res (2003) 1.08
The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis. Oncogene (2005) 1.08
Collapsing glomerulopathy in adult still's disease. Am J Kidney Dis (2004) 1.07
Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer (2011) 1.07
Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol (2005) 1.07
Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. Cell Oncol (2007) 1.06
A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP. J Biol Chem (2007) 1.05
SEPT9_v4 expression induces morphological change, increased motility and disturbed polarity. J Pathol (2005) 1.05
Use of the γ-H2AX assay to investigate DNA repair dynamics following multiple radiation exposures. PLoS One (2013) 1.05
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol (2011) 1.04
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res (2008) 1.04
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med (2009) 1.03
Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res (2011) 1.02
Traumatic rupture of an intracranial dermoid cyst: Case report and literature review. Surg Neurol Int (2013) 1.02
BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol (2009) 1.02
The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res (2002) 1.02
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology (2014) 1.01
Generation of a non-small cell lung cancer transcriptome microarray. BMC Med Genomics (2008) 1.01
Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer (2007) 1.01
Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res (2011) 1.01
BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem (2002) 1.00